Baxter International (BAX) Stock: Charts & Financials

Baxter International Inc. (BAX)BAXBaxter International Inc.

About Baxter International Inc.

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Deerfield, IL

37,500 employees

www.baxter.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Andrew Hider

View full financials

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Total Current Assets	6.85B	6.85B	6.87B	6.93B	6.75B	7.04B	8.85B	8.86B	8.59B
Cash & Cash Equivalents	2.02B	2.02B	1.97B	1.73B	1.69B	2.29B	1.76B	1.42B	2.10B
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	2.02B	2.02B	1.97B	1.73B	1.69B	2.29B	1.76B	1.42B	2.10B
Accounts Receivable	1.70B	1.70B	1.93B	1.78B	1.77B	1.65B	1.73B	1.73B	2.64B
Inventory	2.32B	2.32B	2.23B	2.46B	2.38B	2.17B	2.05B	2.10B	2.98B
Total Assets	19.85B	19.85B	20.05B	21.07B	21.05B	21.30B	25.78B	26.68B	26.31B
Property, Plant & Equipment	3.19B	3.19B	3.19B	3.08B	3.09B	3.02B	3.18B	3.16B	4.84B
Goodwill	4.90B	4.90B	4.93B	5.40B	5.39B	5.34B	5.28B	5.78B	6.00B
Intangible Assets	4.22B	4.22B	4.37B	4.80B	4.95B	5.08B	5.22B	5.45B	5.74B
Long-Term Investments	113.00M	113.00M	103.00M	126.00M	114.00M	117.00M	109.00M	126.00M	168.00M
Total Current Liabilities	3.69B	3.69B	2.97B	3.77B	2.94B	3.48B	6.51B	6.20B	6.13B
Accounts Payable	1.09B	1.09B	999.00M	953.00M	995.00M	963.00M	968.00M	841.00M	1.25B
Short-Term Debt	842.00M	842.00M	1.00M	755.00M	8.00M	662.00M	2.75B	2.50B	2.47B
Total Liabilities	13.83B	13.83B	13.95B	13.85B	13.75B	14.25B	18.76B	18.73B	18.60B
Long-Term Debt	8.62B	8.62B	9.47B	8.75B	9.49B	9.41B	10.37B	10.44B	10.44B
Total Debt	9.69B	9.69B	9.78B	9.71B	9.72B	10.31B	13.45B	13.19B	13.34B
Net Debt (Cash)	7.67B	7.67B	7.81B	7.99B	8.04B	8.02B	11.69B	11.77B	11.25B
Total Shareholders' Equity	6.04B	6.04B	6.13B	7.24B	7.32B	7.08B	6.96B	7.87B	7.64B
Common Stock	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M
Retained Earnings	13.69B	13.69B	13.71B	14.84B	14.97B	14.97B	14.93B	15.53B	15.54B
Current Ratio	1.85	1.85	2.31	1.84	2.30	2.02	1.36	1.43	1.40
Debt to Equity Ratio	1.60	1.60	1.60	1.34	1.33	1.46	1.93	1.68	1.75

Quarterly Report

TTM

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Quarter ended Jun 2024

Total Current Assets

6.85B

6.87B

6.93B

6.75B

7.04B

8.85B

8.86B

8.59B

Cash & Cash Equivalents

2.02B

1.97B

1.73B

1.69B

2.29B

1.76B

1.42B

2.10B

Short-Term Investments

0.00

Cash & Short-Term Investments

2.02B

1.97B

1.73B

1.69B

2.29B

1.76B

1.42B

2.10B

Accounts Receivable

1.70B

1.93B

1.78B

1.77B

1.65B

1.73B

2.64B

Inventory

2.32B

2.23B

2.46B

2.38B

2.17B

2.05B

2.10B

2.98B

Total Assets

19.85B

20.05B

21.07B

21.05B

21.30B

25.78B

26.68B

26.31B

Property, Plant & Equipment

3.19B

3.08B

3.09B

3.02B

3.18B

3.16B

4.84B

Goodwill

4.90B

4.93B

5.40B

5.39B

5.34B

5.28B

5.78B

6.00B

Intangible Assets

4.22B

4.37B

4.80B

4.95B

5.08B

5.22B

5.45B

5.74B

Long-Term Investments

113.00M

103.00M

126.00M

114.00M

117.00M

109.00M

126.00M

168.00M

Total Current Liabilities

3.69B

2.97B

3.77B

2.94B

3.48B

6.51B

6.20B

6.13B

Accounts Payable

1.09B

999.00M

953.00M

995.00M

963.00M

968.00M

841.00M

1.25B

Short-Term Debt

842.00M

1.00M

755.00M

8.00M

662.00M

2.75B

2.50B

2.47B

Total Liabilities

13.83B

13.95B

13.85B

13.75B

14.25B

18.76B

18.73B

18.60B

Long-Term Debt

8.62B

9.47B

8.75B

9.49B

9.41B

10.37B

10.44B

Total Debt

9.69B

9.78B

9.71B

9.72B

10.31B

13.45B

13.19B

13.34B

Net Debt (Cash)

7.67B

7.81B

7.99B

8.04B

8.02B

11.69B

11.77B

11.25B

Total Shareholders' Equity

6.04B

6.13B

7.24B

7.32B

7.08B

6.96B

7.87B

7.64B

Common Stock

683.00M

Retained Earnings

13.69B

13.71B

14.84B

14.97B

14.93B

15.53B

15.54B

Current Ratio

1.85

2.31

1.84

2.30

2.02

1.36

1.43

1.40

Debt to Equity Ratio

1.60

1.34

1.33

1.46

1.93

1.68

1.75

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	6.87B	8.85B	9.60B	8.01B	8.87B	8.41B	7.50B	5.96B
Cash & Cash Equivalents	1.97B	1.76B	3.08B	1.72B	2.95B	3.73B	3.33B	1.84B
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	1.97B	1.76B	3.08B	1.72B	2.95B	3.73B	3.33B	1.84B
Accounts Receivable	1.93B	1.73B	1.77B	2.62B	2.71B	2.08B	1.90B	1.84B
Inventory	2.23B	2.05B	1.92B	2.68B	2.45B	1.92B	1.65B	1.67B
Total Assets	20.05B	25.78B	28.28B	28.29B	33.52B	20.02B	18.19B	15.72B
Property, Plant & Equipment	3.19B	3.18B	3.21B	5.24B	5.81B	5.33B	5.12B	4.53B
Goodwill	4.93B	5.28B	5.79B	6.45B	9.84B	3.22B	3.03B	3.00B
Intangible Assets	4.37B	5.22B	5.92B	6.79B	7.79B	1.67B	1.47B	1.41B
Long-Term Investments	103.00M	109.00M	136.00M	247.00M	195.00M	135.00M	76.00M	44.00M
Total Current Liabilities	2.97B	6.51B	6.50B	4.75B	4.24B	3.33B	3.23B	2.81B
Accounts Payable	999.00M	968.00M	881.00M	1.11B	1.25B	1.04B	892.00M	998.00M
Short-Term Debt	84.00M	2.75B	2.67B	1.40B	511.00M	406.00M	541.00M	4.00M
Total Liabilities	13.95B	18.76B	19.81B	22.39B	24.40B	11.29B	10.28B	7.85B
Long-Term Debt	9.68B	10.37B	11.09B	15.23B	17.15B	5.79B	4.81B	3.48B
Total Debt	10.00B	13.45B	14.11B	17.20B	18.31B	6.80B	5.96B	3.48B
Net Debt (Cash)	8.04B	11.69B	11.04B	15.48B	15.36B	3.07B	2.63B	1.65B
Total Shareholders' Equity	6.13B	6.96B	8.40B	5.83B	9.08B	8.69B	7.88B	7.84B
Common Stock	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M	683.00M
Retained Earnings	13.71B	14.93B	16.11B	14.05B	17.07B	16.33B	15.72B	15.07B
Current Ratio	2.31	1.36	1.48	1.69	2.09	2.52	2.32	2.12
Debt to Equity Ratio	1.63	1.93	1.68	2.95	2.02	0.78	0.76	0.44

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Total Current Assets

6.87B

8.85B

9.60B

8.01B

8.87B

8.41B

7.50B

5.96B

Cash & Cash Equivalents

1.97B

1.76B

3.08B

1.72B

2.95B

3.73B

3.33B

1.84B

Short-Term Investments

0.00

Cash & Short-Term Investments

1.97B

1.76B

3.08B

1.72B

2.95B

3.73B

3.33B

1.84B

Accounts Receivable

1.93B

1.73B

1.77B

2.62B

2.71B

2.08B

1.90B

1.84B

Inventory

2.23B

2.05B

1.92B

2.68B

2.45B

1.92B

1.65B

1.67B

Total Assets

20.05B

25.78B

28.28B

28.29B

33.52B

20.02B

18.19B

15.72B

Property, Plant & Equipment

3.19B

3.18B

3.21B

5.24B

5.81B

5.33B

5.12B

4.53B

Goodwill

4.93B

5.28B

5.79B

6.45B

9.84B

3.22B

3.03B

3.00B

Intangible Assets

4.37B

5.22B

5.92B

6.79B

7.79B

1.67B

1.47B

1.41B

Long-Term Investments

103.00M

109.00M

136.00M

247.00M

195.00M

135.00M

76.00M

44.00M

Total Current Liabilities

2.97B

6.51B

6.50B

4.75B

4.24B

3.33B

3.23B

2.81B

Accounts Payable

999.00M

968.00M

881.00M

1.11B

1.25B

1.04B

892.00M

998.00M

Short-Term Debt

84.00M

2.75B

2.67B

1.40B

511.00M

406.00M

541.00M

4.00M

Total Liabilities

13.95B

18.76B

19.81B

22.39B

24.40B

11.29B

10.28B

7.85B

Long-Term Debt

9.68B

10.37B

11.09B

15.23B

17.15B

5.79B

4.81B

3.48B

Total Debt

10.00B

13.45B

14.11B

17.20B

18.31B

6.80B

5.96B

3.48B

Net Debt (Cash)

8.04B

11.69B

11.04B

15.48B

15.36B

3.07B

2.63B

1.65B

Total Shareholders' Equity

6.13B

6.96B

8.40B

5.83B

9.08B

8.69B

7.88B

7.84B

Common Stock

683.00M

Retained Earnings

13.71B

14.93B

16.11B

14.05B

17.07B

16.33B

15.72B

15.07B

Current Ratio

2.31

1.36

1.48

1.69

2.09

2.52

2.32

2.12

Debt to Equity Ratio

1.63

1.93

1.68

2.95

2.02

0.78

0.76

0.44

Balance Sheet

Quarterly Balance Sheet (USD)

Annual Balance Sheet (USD)